Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine plus intravenous omega-3 fish oil for unresectable pancreatic adenocarcinoma
2009-009470-27Phase 2Completed
- Sponsor
- University Hospitals of Leicester NHS Trust
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Lipidem and gemcitabine in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC), sponsored by University Hospitals of Leicester NHS Trust. Primary endpoints: Objective response rate and Study completion endpoint. Started Apr 2009; status: completed.
02
Drugs
Lipidemgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2009-009470-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009470-27.